Summary: Nyxoah described its Q1 2024 economic and operating outcomes, highlighting sizeable progress with its Genio program, a leadless and battery-cost-free hypoglossal neurostimulation therapy for obstructive snooze apnea (OSA). The Aspiration US pivotal study reached co-key … [Read more...]
Genio Neurostimulator Reduces Sleep Apnea Severity
Nyxoah SAs Desire US pivotal analyze, made to assist the advertising and marketing authorization of the Genio hypoglossal nerve stimulation procedure for obstructive sleep apnea in the United States, achieved a statistically substantial reduction in the co-key endpoints of … [Read more...]